Turn Therapeutics Inc.

Conversation Centered Around Healthcare Communications and Pandemic Preparedness The post Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D. appeared first on Turn Therapeutics.

LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been named as one of the “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine. “We are honored to have our GX-03 technology be recognized as a […] The post Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine appeared first on Turn Therapeutics.

Data is the currency of pharma because it represents the only form of wealth that cannot be inflated by influencers or fancy marketing campaigns: statistically-validated reality viewed on pages and pages of datasets. The post Data as Currency for Pharma appeared first on Turn Therapeutics.

LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company’s licensing and partnership […] The post Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications appeared first on Turn Therapeutics.

Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities The post Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline appeared first on Turn Therapeutics.

Below is a recording of Turn Therapeutics Public Shareholder Session hosted by Founder & CEO Bradley Burnam on October 22, 2025. The post Recording of Public Shareholder Session – October 22, 2025 appeared first on Turn Therapeutics.

Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy The post Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones appeared first on Turn Therapeutics.

LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) — Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam. “It is an uncommon step to maintain constant engagement with shareholders, partners, and the broader […] The post Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025 appeared first on Turn Therapeutics.

Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research The post Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors appeared first on Turn Therapeutics.

Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs The post Turn Therapeutics Appoints Arthur Golden to Board of Directors appeared first on Turn Therapeutics.